TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07108114: SLV-324 Treatment of Metastatic Solid Tumors

Sponsor: Solve Therapeutics · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 70 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$376,992

Rescue Site Savings

+$251,328

Unlock Full NCT07108114 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07108114 Rescue Dossier →